Latest News and Press Releases
Want to stay updated on the latest news?
-
HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to tumor sitesPotent in vitro anti-tumor efficacy...
-
- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...
-
PORT HUENEME, CA--(Marketwired - May 21, 2013) - Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that Frank Oaks, President & CEO and Darrell Brookstein,...
-
PORT HUENEME, CA--(Marketwire - Mar 13, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of results from a...
-
PORT HUENEME, CA--(Marketwire - Feb 19, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company exceeded its 2012 plan...
-
PORT HUENEME, CA--(Marketwire - Feb 6, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company has submitted a...
-
PORT HUENEME, CA--(Marketwire - Jan 22, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company has successfully...
-
PORT HUENEME, CA--(Marketwire - Jan 18, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of...
-
PORT HUENEME, CA--(Marketwire - Jan 2, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT), the world leader in sustainable...
-
PORT HUENEME, CA--(Marketwire - Dec 12, 2012) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT), the world leader in sustainable...